12 April 2026 · 8 min

[PLACEHOLDER] On mechanism-class mapping in oncology deal flow

Why grouping deals by indication understates the structural shift toward antibody-drug conjugates and radioligand therapy — and what a cleaner taxonomy reveals.

This is placeholder MDX content. The methodology essays will live here, written in Markdown with embedded components where useful (charts, pull quotes, inline data).

Why this matters

[PLACEHOLDER] Two paragraphs framing the problem. Editorial tone — not blog, not memo. The reader is a generalist principal who is rigorous but not a sector specialist.

A pull quote in serif italic, set apart from the body, used sparingly to mark a turn in the argument.

A cleaner taxonomy

[PLACEHOLDER] Body text continues. Inline references, footnotes, and embedded charts can be added as React/Astro components. Two columns of body text are not used — single editorial column with generous margins.

What this implies for diligence

[PLACEHOLDER] Closing section. No bullet list summary; the prose is the conclusion.